On August 20, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.
Auris Medical Holding AG announced that it will provide an update on its development program with AM-111 for the treatment of acute inner ear hearing loss on Thursday, January 4, 2018.
Auris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Auris Medical, the developer of post-trauma treatments for acute inner ear tinnitus and acute inner ear hearing loss via intratympanic injection, has announced a proposed IPO.
Read More